Economic evaluation of the treatment of patients with HER2 positive breast cancer

• Grant number: 22/12127-4
• Support Opportunities: Scholarships in Brazil - Doctorate
• Start date: January 01, 2023
• End date: December 31, 2025
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Maria Del Pilar Estevez Diz
• Grantee: Carlos Henrique Botelho
• Host Institution: Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira (ICESP). Coordenadoria de Serviços de Saúde (CSS). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

According to estimates by the World Health Organization (WHO) in 2019, cancer is among the 4 leading causes of death in upper middle-income countries and has already reached the first position in some countries, constituting the most important barrier to the increase in life expectancy in the world.The prevalence of cancer in developing countries has reached levels close to those recorded in developed countries. It is estimated that in 2020 there were 19.3 million new cases of cancer and 10 million deaths, with 2.3 million new cases of breast cancer.This type of cancer is the main cause of death among women, corresponding to 685,000 deaths and representing 6.9% of all cancer deaths in 2020. Brazil is in an epidemiological transition, thus an increase in the incidence of diseases in developed countries.In Brazil, for each year of the triennium 2020-2022, there are an estimated 625,000 new cases of cancer, of which 66,280 are new cases of breast cancer, with an estimated risk of 61.61 cases per 100,000 women.Although breast cancer has a higher mortality rate (12.9/100,000) than any other cancer, the case fatality rate is relatively low, as the mortality rate is less than one third of the incidence. According to Brazilian statistics, breast cancer is the most prevalent cancer, with approximately 8.7 million survivors in 2012.There is growing evidence regarding the influence of innovations in cancer treatments on the chance of survival of patients after diagnosis and treatment of breast cancer, as well as in terms of reducing the risk of recurrence and improving the quality of life during treatment. Within this context, the assessment of health technologies is an important instrument for the rational allocation of scarce health resources, as well as contemplating elements that help to fulfill the principles of the Unified Health System regarding equity, integrality and universality in health care for the Brazilian population. The study of costs and outcomes resulting from the treatment of breast cancer, based on the economic evaluation of health technologies, is a fundamental step for the elaboration of strategies for the management of health resources and the planning of public policies to support the prevention of morbidities and the health promotion in the country. The present work has as general objective to carry out an analysis of costs and outcomes in the treatment of patients with non-metastatic and metastatic breast cancer within the scope of the Unified Health System (SUS).